VivoSeq
Dermatology

Non-Segmental Vitiligo

4

Pipeline Programs↗

6

Active Trials↗

8

Companies Involved↗

Non-segmental Vitiligo is an early-stage landscape with 4 programs across 8 companies. The most active players are Novartis, Idorsia Pharmaceuticals Ltd., Merck & Co.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

19/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

GIA632

Novartis

Act-777991

Idorsia Pharmaceuticals Ltd.

MK-6194

Merck & Co.

Phase 31

Ritlecitinib

Pfizer

Approved
No programs

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Not yet recruiting2 · 29%
Terminated1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Recruiting·Incyte logoIncyte·Phase 3·NCT06804811·250 enrolled
A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Recruiting·Incyte logoIncyte·Phase 3·NCT06548360·180 enrolled
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
Recruiting·Novartis logoNovartis·Phase 2·NCT07431177·210 enrolled
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
Active, not recruiting·Pfizer logoPfizer·Phase 3·NCT06072183·1,571 enrolled
Efficacy and Safety of Ruxolitinib Phosphate Cream Combined With Corticosteroids in Patients With Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
Not yet recruiting·—·N/A·NCT07673640·300 enrolled
A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo
Not yet recruiting·Idorsia Pharmaceuticals Ltd. logoIdorsia Pharmaceuticals Ltd.·Phase 2·NCT07667569·30 enrolled
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Non-Segmental Vitiligo
Terminated·Merck & Co. logoMerck & Co.·Phase 2·NCT06113328·169 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)